日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Understanding structure-guided variant effect predictions using 3D convolutional neural networks

利用三维卷积神经网络理解结构引导的变异效应预测

Ramakrishnan, Gayatri; Baakman, Coos; Heijl, Stephan; Vroling, Bas; van Horck, Ragna; Hiraki, Jeffrey; Xue, Li C; Huynen, Martijn A

Facilities that make the PDB data collection more powerful

使PDB数据收集更强大的设施

Lange, Joanna; Baakman, Coos; Pistorius, Arthur; Krieger, Elmar; Hooft, Rob; Joosten, Robbie P; Vriend, Gert

No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model

在东莨菪碱激发模型中,亚治疗剂量的多奈哌齐和EVP-6124在健康老年受试者中未显示出协同作用。

Baakman, Anne Catrien; Alvarez-Jimenez, Ricardo; Loewen, Gordon; de Kam, Marieke L; Broekhuizen, Karen; Hilt, Dana C; Groeneveld, Geert Jan

MetaDome: Pathogenicity analysis of genetic variants through aggregation of homologous human protein domains

MetaDome:通过同源人类蛋白质结构域的聚集进行遗传变异致病性分析

Wiel, Laurens; Baakman, Coos; Gilissen, Daan; Veltman, Joris A; Vriend, Gerrit; Gilissen, Christian

An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine

一项使用美卡拉明的抗尼古丁认知挑战模型与使用东莨菪碱的抗毒蕈碱认知挑战模型的比较研究

Baakman, Anne Catrien; Alvarez-Jimenez, Ricardo; Rissmann, Robert; Klaassen, Erica S; Stevens, Jasper; Goulooze, Sebastiaan C; den Burger, Jeroen C G; Swart, Eleonora L; van Gerven, Joop M A; Groeneveld, Geert Jan

First in human study with a prodrug of galantamine: Improved benefit-risk ratio?

首次在人体中使用加兰他敏前药:获益风险比是否提高?

Baakman, Anne C; 't Hart, Ellen; Kay, Denis G; Stevens, Jasper; Klaassen, Erica S; Maelicke, Alfred; Groeneveld, Geert J

Systematic generation of in vivo G protein-coupled receptor mutants in the rat

大鼠体内 G 蛋白偶联受体突变体的系统生成

R van Boxtel, B Vroling, P Toonen, I J Nijman, H van Roekel, M Verheul, C Baakman, V Guryev, G Vriend, E Cuppen